Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Chemclin Diagnostics Co's Revenue for the
three
months ended in Mar. 2026 was ¥73.3 Mil. Chemclin Diagnostics Co's average Accounts Receivable for the
three
months ended in Mar. 2026 was ¥11.2 Mil.
Hence, Chemclin Diagnostics Co's Receivables Turnover for the
three
months ended in Mar. 2026 was 6.55.
Chemclin Diagnostics Co (SHSE:688468) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Chemclin Diagnostics Co Receivables Turnover Related Terms
Chemclin Diagnostics Co Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Chemclin Diagnostics Co's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chemclin Diagnostics Co Receivables Turnover Chart
SHSE:688468 vs TMO, DHR, IDXX: Receivables Turnover Comparison
For the Diagnostics & Research subindustry, Chemclin Diagnostics Co's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chemclin Diagnostics Co Receivables Turnover vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Chemclin Diagnostics Co's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Chemclin Diagnostics Co's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chemclin Diagnostics Co (SHSE:688468) has a Receivables Turnover of 6.55 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Chemclin Diagnostics Co and its competitors. According to the industry distribution chart, Chemclin Diagnostics Co ranks #6 out of 202 companies in the Medical Diagnostics & Research industry, placing it in the top 3%.
Is Chemclin Diagnostics Co's Receivables Turnover too high?
Chemclin Diagnostics Co's current Receivables Turnover is 6.55. The Medical Diagnostics & Research industry median Receivables Turnover is 5.38. Chemclin Diagnostics Co's value of 6.55 is 21.9% above this industry median. Based on the distribution chart, Chemclin Diagnostics Co ranks #6 out of 202 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Chemclin Diagnostics Co has a GF Score™ of 72/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Chemclin Diagnostics Co's Receivables Turnover compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Chemclin Diagnostics Co ranks #6 out of 202 companies for Receivables Turnover. This places Chemclin Diagnostics Co in the top 3% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.38. Chemclin Diagnostics Co's value of 6.55 is 21.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Diagnostics & Research company?
The median Receivables Turnover among Medical Diagnostics & Research companies is 5.38, based on 202 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chemclin Diagnostics Co's current Receivables Turnover of 6.55 is 21.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Chemclin Diagnostics Co and its competitors. For the Medical Diagnostics & Research industry, the median Receivables Turnover is 5.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chemclin Diagnostics Co's current Receivables Turnover is 6.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chemclin Diagnostics Co stock overvalued right now?
Based on GuruFocus' analysis, Chemclin Diagnostics Co (SHSE:688468) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥5.69, compared to a current price of ¥6.29 — trading 10.5% above its estimated fair value. The current Receivables Turnover is 6.55 and 21.9% above the Medical Diagnostics & Research industry median of 5.38. Chemclin Diagnostics Co's overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Chemclin Diagnostics Co (SHSE:688468), the current Receivables Turnover is 6.55 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chemclin Diagnostics Co (SHSE:688468) Overvalued in 2026?
Based on GuruFocus' analysis, Chemclin Diagnostics Co stock appears to be overvalued.
The current stock price of ¥6.29 is trading 10.5% above its estimated GF Value™ of ¥5.69.
GuruFocus considers Chemclin Diagnostics Co to be Modestly Overvalued.
Key valuation signals for SHSE:688468:
Receivables Turnover: 6.55
GF Value™: ¥5.69 vs. price of ¥6.29 (10.5% above fair value)
Industry Position: 21.9% above the Medical Diagnostics & Research median (#6 of 202)
No single metric tells the full story. See the SHSE:688468 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chemclin Diagnostics Co Ltd is engaged in the development, production and sales of clinical immunochemiluminescence diagnostic testing reagents and instruments.
72GF Score
Get the complete analysis for SHSE:688468
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688468 has been successfully added to your 
